13F Holdings
中文EN

MGX Metagenomi Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1785279 · Fiscal year ends 12/31

Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-50.7%
TTM net income YoY-10.2%
TTM EPS YoY-23.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-415.5%
Net margin-384.6%
FCF margin-392.0%
EBITDA margin-392.0%

Returns

ROE-49.0%
ROA-34.7%
ROIC (approx.)-49.5%
Asset turnover0.09x

Leverage & solvency

Liabilities / assets30.0%
Debt / equity0.00x
Current ratio6.43x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.02x
Accruals ratio0.5%
Payout ratio—
Capex / revenue1.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31
Income statement
Revenue$25.21M$52.30M$44.76M
R&D expense$94.43M$109.18M$94.40M
SG&A expense$26.79M$32.02M$28.84M
Operating income-$96.01M-$88.90M-$78.49M
Pretax income-$87.93M-$83.57M-$60.23M
Income tax-$58,000-$5.51M$8.03M
Net income-$87.87M-$78.06M-$68.25M
EBITDA-$90.70M-$83.49M-$74.28M
EPS (basic)-2.36-2.36-20.05
EPS (diluted)-2.36-2.36-20.05
Weighted avg. shares (diluted)37.25M33.03M3.40M
Balance sheet
Cash & equivalents$41.72M$32.63M$145.85M
Short-term investments$119.08M$220.92M$130.58M
Receivables$305,000$1.26M$2.45M
Current assets$165.54M$257.96M$278.27M
PP&E, net$12.29M$17.74M$21.54M
Total assets$221.10M$324.60M$364.84M
Current liabilities$22.93M$37.31M$68.86M
Total liabilities$62.51M$89.74M$149.67M
Shareholders' equity$158.60M$234.86M-$135.58M
Shares outstanding37.62M37.42M3.40M
Cash flow statement
Operating cash flow-$88.89M-$109.07M-$91.41M
Capital expenditure$574,000$3.11M$9.81M
Free cash flow-$89.47M-$112.19M-$101.22M
Investing cash flow$103.53M-$88.16M$45.73M
Financing cash flow-$356,000$84.01M$1.01M
Depreciation & amortization$5.32M$5.41M$4.21M
Stock-based compensation$11.85M$16.20M$6.92M

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.